Duomeisu

**Duomeisu** is a pegylated liposomal formulation of doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic developed by CSPC Pharmaceutical Group Limited (specifically CSPC Ouyi Pharmaceutical). It intercalates into DNA, inhibits topoisomerase II, generates reactive oxygen species, and induces apoptosis, primarily for treating ovarian cancer, breast cancer (including HER2-negative metastatic), lymphoma, multiple myeloma, and other solid tumors. The liposomal encapsulation enhances tumor penetration, prolongs circulation, and reduces cardiotoxicity compared to conventional doxorubicin, with typical dosing at 40 mg/m² intravenously every 28 days. Approved in China since 2012 for AIDS-related Kaposi’s sarcoma and later for additional indications, it has demonstrated efficacy in platinum-resistant ovarian cancer and anthracycline-pretreated breast cancer patients.[1][2][3][4][7][9]

Brand names

Duomeisu

Other names

Doxorubicin Hydrochloride Liposome InjectionPegylated liposomal doxorubicin (Duomeisu)